Eisai shares tank after partner Biogen’s Alzheimer’s data disappoints
TOKYO (Reuters) – Shares in Japanese drug maker Eisai Co fell nearly 10 percent early on Thursday after news of disappointing data for partner Biogen Inc’s experimental Alzheimer’s drug.
Eisai was down 7 percent at 8,228 yen at 0109 GMT, after falling to as low as 7975.0 yen.
Its shares had jumped to a record high in March driven by promising results of Biogen’s experimental drug.
(Reporting by Ayai Tomisawa; Editing by Chang-Ran Kim)
- Biogen Inc